Sage Therapeutics, Inc. (SAGE) Is At $141.19 Formed Wedge; Maxar Technologies LTD. (MAXR) SI Increased By 5.57%

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Maxar Technologies LTD. (NYSE:MAXR) had an increase of 5.57% in short interest. MAXR’s SI was 3.63 million shares in April as released by FINRA. Its up 5.57% from 3.44 million shares previously. With 343,000 avg volume, 11 days are for Maxar Technologies LTD. (NYSE:MAXR)’s short sellers to cover MAXR’s short positions. The SI to Maxar Technologies LTD.’s float is 6.5%. The stock increased 0.64% or $0.29 during the last trading session, reaching $45.4. About 151,619 shares traded. Maxar Technologies Ltd. (NYSE:MAXR) has declined 32.35% since April 25, 2017 and is downtrending. It has underperformed by 43.90% the S&P500.

Sage Therapeutics, Inc. (SAGE) formed wedge down with $129.89 target or 8.00% below today’s $141.19 share price. Sage Therapeutics, Inc. (SAGE) has $6.46 billion valuation. The stock decreased 2.96% or $4.3 during the last trading session, reaching $141.19. About 365,121 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since April 25, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Investors sentiment increased to 1.49 in Q4 2017. Its up 0.28, from 1.21 in 2017Q3. It improved, as 27 investors sold Sage Therapeutics, Inc. shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. State Board Of Administration Of Florida Retirement Sys invested in 0.01% or 20,992 shares. Emerald Advisers Incorporated Pa reported 168,785 shares or 1.07% of all its holdings. Alyeska Inv Grp Inc L P stated it has 155,629 shares. Boothbay Fund Management owns 3,908 shares. Ameritas Investment Prns Inc reported 3,254 shares or 0.02% of all its holdings. Eagle Asset Mngmt stated it has 0.56% in Sage Therapeutics, Inc. (NASDAQ:SAGE). 38,526 were reported by Rhumbline Advisers. 2.07 million are held by Wellington Grp Limited Liability Partnership. Invesco Limited invested in 47,959 shares or 0% of the stock. Massachusetts-based Amundi Pioneer Asset Inc has invested 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Cwm Limited Liability, Nebraska-based fund reported 6 shares. 28,600 were reported by Strs Ohio. Laurion Cap Management Lp, New York-based fund reported 35,052 shares. Amer Century Cos Incorporated accumulated 29,236 shares. Zeke Capital Advisors Ltd Com has invested 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE).

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on May, 8. They expect $-1.85 EPS, down 21.71% or $0.33 from last year’s $-1.52 per share. After $-1.75 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.71% negative EPS growth.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 57 analyst reports since September 3, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, March 30 by Goldman Sachs. Raymond James initiated the shares of SAGE in report on Tuesday, September 13 with “Outperform” rating. Chardan Capital Markets upgraded Sage Therapeutics, Inc. (NASDAQ:SAGE) on Friday, November 10 to “Buy” rating. The firm has “Buy” rating given on Thursday, October 26 by BMO Capital Markets. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Leerink Swann on Tuesday, June 20. The stock has “Outperform” rating by BMO Capital Markets on Friday, November 17. On Friday, March 11 the stock rating was initiated by Lake Street with “Buy”. The firm has “Buy” rating by Leerink Swann given on Thursday, December 7. The firm earned “Buy” rating on Monday, April 23 by BMO Capital Markets. The stock has “Buy” rating by SunTrust on Thursday, October 19.

Since December 14, 2017, it had 0 insider purchases, and 4 insider sales for $37.32 million activity. 58,139 shares valued at $10.00 million were sold by PAUL STEVEN M on Tuesday, March 6. On Tuesday, April 17 the insider STARR KEVIN P sold $9.96 million. $9.57 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by Robichaud Albert on Thursday, December 14. On Wednesday, January 10 Kanes Stephen sold $7.80 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 44,000 shares.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart